---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-016678"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:02:13.716544+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Axsome settles AUVELITY patent litigation with Teva; generic entry no earlier than 2038-2039

## Summary
- Settlement grants Teva license to sell generic AUVELITY starting Mar 31, 2039 (if pediatric exclusivity) or Sep 30, 2038 (if not).
- All ongoing AUVELITY patent litigation in U.S. District Court for New Jersey will be terminated.
- Agreement is subject to review by the U.S. FTC and U.S. Department of Justice.
- CEO Herriot Tabuteau says settlement reflects strength of Axsome’s IP portfolio and commitment to CNS innovation.

## SEC filing metadata
- accession: 0000950170-25-016678
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017025016678/0000950170-25-016678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017025016678/axsm-20250210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-016678
- JSON: https://secwatch.observer/filing/0000950170-25-016678.json
- Plain text: https://secwatch.observer/filing/0000950170-25-016678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.